Profound neutropenia resulting from interaction between antiretroviral therapy and vinblastine in a patient with HIV-associated Hodgkin's disease.
A HIV infected patient was treated for stage IVB Hodgkin's lymphoma by ABVD (doxorubicine, bleomycine, vinblastine, dacarbazine) chemotherapy and lopinavir-ritonavir based antiretroviral therapy inducing profound life-threatening neutropenia. Vinblastine and lopinavir-ritonavir interaction was managed with lopinavir-ritonavir interruption around chemotherapy administration, with complete remission and immunovirological success after six cycles. This unrecorded strategy is discussed.
Makinson
Alain
A
Infectious Diseases Department, Gui de Chauliac Hospital, CHU Montpellier, France.
Martelli
Nicolas
N
Peyrière
Hélène
H
Turriere
Chrystell
C
Le Moing
Vincent
V
Reynes
Jacques
J
D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D015658:HIV Infections / Q000188:drug therapy*; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D008297:Male; D009503:Neutropenia / Q000139:chemically induced* / Q000188:drug therapy; D012074:Remission Induction; D016896:Treatment Outcome; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects*
D019380:Anti-HIV Agents; D014747:Vinblastine